Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment - Naive, HIV-infected subjects: Week 48 data from the Altair study

Clinical Infectious Diseases

Volumn 51, Issue 7, 2010, Pages 855-864

  Puls, Rebekah L ^a,b   Srasuebkul, Preeyaporn ^a   Petoumenos, Kathy ^a   Boesecke, Christoph ^a   Duncombe, Chris ^c   Belloso, Waldo H ^d   Molina, Jean Michel ^e   Li, Lin ^f   Avihingsanon, Anchalee ^c   Gazzard, Brian ^g   Cooper, David A ^a,b  

^a Coogee Campus ^*  (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^d HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^e SAINT LOUIS HOSPITAL   (France)

^f TAN TOCK SENG HOSPITAL   (Singapore)

^g CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGY; INFECTION; INFESTATION; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VIROLOGY; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DIDEOXYNUCLEOSIDES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 77957842048     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656363     Document Type: Article

References (42)

1. United States Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL .pdf. Published 1 December 2009. Accessed 29 July 2010.
2. López-Cortés LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41:681-690.
3. Patel A, Patel K, Patel J, Shah N, Patel B, Rani S. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr 2004; 37:1166-1169.
4. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20:131-132.
5. Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS 2005; 19:1541-1543.
6. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006; 58:1299-1302.
7. Sathia L, Obiorah I, Taylor G, et al. Concomitant use of nonnucleoside analogue reverse-transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients. AIDS Res Hum Retroviruses 2008; 24:897-901.
8. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine-and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300:530-539.
9. Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the nonnucleoside reverse-transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001; 51:213-217.
10. Jungmann EM, Mercey D, DeRuiter A, et al. Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities? Sex Transm Infect 2001; 77: 441-443.
11. Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16:299-300.
12. De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002; 162:355.
13. Khanlou H, Yeh V, Guyer B, Farthing C. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS 2005; 19(3):135-140.
14. Gallant JE, Rodriguez AE, Weinberg WG, et al; for the ESS30009 Study. Early virological nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192: 1921-1930.
15. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296(7):769-781.
16. Gulick R, Ribaudo H, Shikuma C, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV- 1 infection. N Engl J Med 2004; 350:1850-1861.
17. Mauss S, Milinkovic A, Hoffmann C, et al. Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine. AIDS 2005; 19:101-103.
18. Rey D, Krebs M, Partisani M, et al. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in anti-retroviral- naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2006; 43:530-534.
19. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20:1391-1399.
20. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised noninferiority trial. Lancet 2010; 375:123-131.
21. Moyle G, Higgs C, Teague C, et al. An open-label randomised comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for persons initiating antiretroviral therapy. Antivir Ther 2006; 11:73-78.
22. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4:87-94.
23. Parikh UM, Koontz DL, Chu CK, Schinazi RF, Mellors JW. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother 2005; 49:1139-1144.
24. White KL, Chen JM, Feng JY, et al. The K65R reverse-transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir Ther 2006; 11:155-163.
25. United States National Institutes of Health. ALTAIR - alternative antiretroviral strategies: a comparison of three initial regimens. http:// clinicaltrials.gov/ct2/show/NCT00335322. Published 8 June 2006. Updated 24 November 2009. Accessed 30 July 2010.
26. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145.
27. Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large nonclinical sample. Br J Clin Psychol 2005; 44:227-239.
28. Brew B. HIV neurology. Contemporary Neurology Series. New York: Oxford University Press. 2001.
29. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-47.
30. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments. AIDS Care 2000; 12:255-266.
31. Ribaudo H, Lennox J, Currier J, et al. Virologic failure end point definition in clinical trials: is using HIV-1 RNA threshold <200 copies/ mL better than <50 copies/mL? an analysis of ACTG studies. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. 2009. Abstract 580.
32. French M, Amin J, Roth N, et al; for the OzCombo 2 investigators. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: the OzCombo 2 study. HIV Clin Trials 2002; 3:177-185.
33. French MA. Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4:16-21.
34. Molina JM, Andrade-Villanueva J, Echevarria J, et al; for the CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-655.
35. Daar E, Tierney C, Fischl M, et al; for the ACTGA5202 Study Team. ACTG 5202: final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-naive HIV-infected patients. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. 2010. Abstract 59LB.
36. Elion R, Cohen C, deJesus E, et al; for the COL40263 Study Team. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naive subjects: a 48- week pilot study. HIV Clin Trials 2006; 7:324-333.
37. Ferrer E, Gatell JM, Sanchez P, et al. Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study. AIDS Res Hum Retroviruses 2008; 24:931-934.
38. Eron J Jr, Yeni P, Gathe J Jr, et al; for the KLEAN Study Team. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomized noninferiority trial. Lancet 2006; 368:476-482.
39. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir, emtricitabine and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
40. Llibre JM, Bonjoch A, Iribarren J, et al; for the HIV Conference Call Study Group. Targeting only reverse transcriptase with zidovudine/ lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study. HIV Med 2008; 9: 508-513.
41. Stephan C, Dauer B, Khaykin P, et al. Quadruple nucleos(t)ide reverse-transcriptase inhibitors-only regimen of tenofovir plus zidovudine/ lamivudine/abacavir in heavily pretreated HIV-1 infected patients: salvage therapy or backbone only? Curr HIV Res 2009; 7:320-326.
42. Stürmer M, Staszewski S, Doerr HW. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Antivir Ther 2007; 12:695-703.